<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166036</url>
  </required_header>
  <id_info>
    <org_study_id>1038-2004</org_study_id>
    <nct_id>NCT00166036</nct_id>
  </id_info>
  <brief_title>Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells</brief_title>
  <acronym>STOPCAP</acronym>
  <official_title>Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells: Comparison of Atorvastatin With Pravastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were
      randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily.
      Oxidative stress (dROMs assay that measures lipid hydroperoxides, plasma thiobarbituric acid
      reactive substances [TBARS], and aminothiol levels) and brachial artery flow-mediated
      dilation (FMD) were measured at baseline and after 12 weeks of statin therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with a high cholesterol level, diabetes or metabolic syndrome (collection of
      abnormalities such as high blood pressure, high triglyceride levels [fat], obesity, high
      blood glucose level) have an increased risk of developing a hardening of the arteries and
      heart disease.

      A group of medications called statins, commonly used worldwide to lower cholesterol levels,
      are known to reduce the risk of heart disease through their effects on reducing cholesterol
      levels. These medications also have effects beyond the lowering of cholesterol that may help
      mediate their beneficial effects on the heart and blood vessels.

      These include a reduced production of molecules that harm the arteries such as reactive
      oxygen species (ROS) and increasing the number of stem cells that help repair vessels, called
      endothelial progenitor cells (EPCs).

      Recent studies have shown that different statins might have different effects on protecting
      people from developing heart disease. These differences may be due to differences in these
      non-cholesterol lowering processes, and are the subject of this study.

      Standard of Care:

      The two statins that will be used in this study, pravastatin (Pravachol ®) and atorvastatin
      (Lipitor®), are approved for use in people with a high cholesterol level or heart disease.
      These medications are generally very well tolerated with minimal side effects. They are not
      approved for use in patients to increase the level of EPCs or to reduce the production of
      ROS, and therefore are considered experimental for this indication. Currently there are no
      drugs that are specifically approved for these indications.

      How the Problem Will be Studied:

      These statins will be given to patients who have high cholesterol and either diabetes or the
      metabolic syndrome once a day for 12 weeks. We, the investigators at Emory, will measure the
      level of EPCs and ROS before and during the administration of the statin. We will also
      investigate how well the blood vessels dilate in response to these medications by performing
      an imaging study of the forearm artery using ultrasound.

      The study is blinded and there is an equal chance of receiving either atorvastatin 10mg or
      pravastatin 80mg which are likely to lower cholesterol level by a similar amount.

      How Research Will Advance Scientific Knowledge:

      The goal of this study is to determine if atorvastatin will increase the number of
      circulating EPCs and reduce the production of ROS more than pravastatin. This may help
      explain the differences between these drugs that have been observed in some recently
      published trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels</measure>
    <time_frame>Baseline &amp;12 Weeks</time_frame>
    <description>Oxidative stress was assessed with plasma thiobarbituric acid reactive substance (TBARS) levels (an index of lipid peroxidation).Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Flow-mediated Dilatation (FMD)</measure>
    <time_frame>Baseline &amp; 12 Weeks</time_frame>
    <description>Flow-mediated dilatation (FMD) of the brachial artery was used to asses Endothelial Function. The endothelium, by releasing nitric oxide (NO), promotes vasodilation and inhibits inflammation, thrombosis, and vascular smooth muscle cell proliferation.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 10MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>12 Weeks of Oral Atorvastatin 10 mg therapy.</description>
    <arm_group_label>Atorvastatin 10MG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>12 Weeks of Oral Pravastatin 80 mg therapy.</description>
    <arm_group_label>Pravastatin 80mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females without child bearing potential aged 21-80 years

          -  Fasting low-density lipoprotein (LDL) level &gt; 120mg/dL.

          -  Either known to be diabetic or have at least 3 components of metabolic syndrome that
             are defined below:

               -  Hypertension defined as blood pressure (BP) &gt; 140 systolic or &gt; 90 mmHg
                  diastolic, or stable medical therapy for documented hypertension;

               -  Fasting glucose &gt; 110 mg/dL;

               -  Waist &gt; 40 inches in males, and &gt; 35 inches in females;

               -  Triglycerides &gt; 150mg/dL; or

               -  High-density lipoprotein (HDL) cholesterol &lt; 40 mg/dL in males and &lt; 50 mg/dL in
                  females.

          -  Able to provide written informed consent

          -  Non-smoker

        Exclusion Criteria:

          -  On any oral antioxidants or lipid lowering medications in the previous 8 weeks

          -  Age &lt; 21 or &gt; 80 years

          -  Premenopausal females with potential for pregnancy

          -  LDL cholesterol level &lt; 120 mg/dl

          -  Initiation or change in dose of any concomitant medical therapy within 2 months before
             the study

          -  Uncontrolled hypertension with BP &gt; 180 mmHg systolic and &gt; 120 mmHg diastolic

          -  Current smoker

          -  Previous intolerance or allergy to statins

          -  Acute infection in previous 4 weeks

          -  History of substance abuse

          -  Uninterpretable Brachial Artery Reactivity Study

          -  Current neoplasm

          -  Chronic renal failure (creatinine &gt; 2.5 mg/dL) or liver failure (liver enzymes &gt; 2X
             normal)

          -  Acute coronary syndrome, heart failure, cerebrovascular accident (CVA), or coronary
             intervention within 3 months

          -  Known aortic stenosis, hypertrophic cardiomyopathy, or symptomatic heart failure.

          -  Inability to give informed consent

          -  Inability to return to Emory for follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshed A Quyyumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Murrow JR, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le NA, Jones D, Quyyumi AA. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 2012 Jan-Feb;6(1):42-9. doi: 10.1016/j.jacl.2011.08.006. Epub 2011 Sep 13.</citation>
    <PMID>22264573</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>June 8, 2012</results_first_submitted>
  <results_first_submitted_qc>August 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2014</results_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Arshed A. Quyyumi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Previous statin or other lipid lowering medications will be discontinued for 2 months. Subjects will be on stable medical therapy for at least 2 months before recruitment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin 10 mg</title>
          <description>Once Daily for 12 Weeks</description>
        </group>
        <group group_id="P2">
          <title>Pravastatin 80 mg</title>
          <description>Once Daily for 12 Weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin 10 mg</title>
          <description>Subject treated with oral Atorvastatin 10 mg for 12 Weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pravastatin 80 mg</title>
          <description>Subject treated with oral Pravastatin 80 mg for 12 Weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="6.6"/>
                    <measurement group_id="B2" value="51.7" spread="10.8"/>
                    <measurement group_id="B3" value="52.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="09"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="08"/>
                    <measurement group_id="B2" value="05"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels</title>
        <description>Oxidative stress was assessed with plasma thiobarbituric acid reactive substance (TBARS) levels (an index of lipid peroxidation).Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
        <time_frame>Baseline &amp;12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg taken daily</description>
          </group>
          <group group_id="O2">
            <title>Pravastatin 80 mg</title>
            <description>Pravastatin 80 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Thiobarbituric Acid Reactive Substance (TBARS) Levels</title>
          <description>Oxidative stress was assessed with plasma thiobarbituric acid reactive substance (TBARS) levels (an index of lipid peroxidation).Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and a biological system's ability to readily detoxify the reactive intermediates or to repair the resulting damage.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
          <units>nmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Flow-mediated Dilatation (FMD)</title>
        <description>Flow-mediated dilatation (FMD) of the brachial artery was used to asses Endothelial Function. The endothelium, by releasing nitric oxide (NO), promotes vasodilation and inhibits inflammation, thrombosis, and vascular smooth muscle cell proliferation.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
        <time_frame>Baseline &amp; 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin 10 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Pravastatin 80 mg</title>
            <description>Pravastatin 80 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Dilatation (FMD)</title>
          <description>Flow-mediated dilatation (FMD) of the brachial artery was used to asses Endothelial Function. The endothelium, by releasing nitric oxide (NO), promotes vasodilation and inhibits inflammation, thrombosis, and vascular smooth muscle cell proliferation.We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function.</description>
          <units>Percentage of brachial artery diameter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.9"/>
                    <measurement group_id="O2" value="6.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin 10 mg</title>
          <description>Subject treated with oral Atorvastatin 10 mg for 12 Weeks.</description>
        </group>
        <group group_id="E2">
          <title>Pravastatin 80 mg</title>
          <description>Subject treated with oral Pravastatin 80 mg for 12 Weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Detection of changes in Oxidative stress with significance requires a much larger cohort study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Arshed A Quyyumi, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404 712 2741</phone>
      <email>aquyyum@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

